Alvotech (ALVO)
5.50
-0.28
(-4.84%)
USD |
NASDAQ |
Oct 12, 16:00
5.50
0.00 (0.00%)
After-Hours: 16:15
Alvotech Gross Profit Margin (Quarterly) : 50.65% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 50.65% |
| March 31, 2026 | 56.47% |
| December 31, 2025 | 63.21% |
| September 30, 2025 | 69.22% |
| June 30, 2025 | 57.39% |
| March 31, 2025 | 40.45% |
| December 31, 2024 | 46.87% |
| September 30, 2024 | 61.31% |
| June 30, 2024 | 77.25% |
| Date | Value |
|---|---|
| March 31, 2024 | -60.56% |
| December 31, 2023 | -5.67% |
| September 30, 2023 | -105.3% |
| June 30, 2023 | -556.2% |
| March 31, 2023 | -146.4% |
| December 31, 2022 | -42.75% |
| September 30, 2022 | -18.91% |
| March 31, 2022 | -1.32K% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -12.30% |
| Return on Invested Capital | -15.48% |
| Profit Margin (Quarterly) | -63.17% |
| Operating Margin (Quarterly) | -11.19% |
| Return on Net Operating Assets | -19.26% |